BioCentury
ARTICLE | Company News

MorphoSys, Daiichi Sankyo deal

May 25, 2009 7:00 AM UTC

Daiichi Sankyo exercised its option to add two new undisclosed cancer targets to a 2006 deal to use MorphoSys' HuCAL technology to generate antibodies against targets from the pharma. Daiichi Sankyo a...